KIRKLAND, QC, March 24, 2016 /CNW Telbec/ - Manitex Capital
Inc. ("Manitex") announces that its' affiliate, Ortho
Regenerative Technologies Inc. ("Ortho RTi"), has filed a new
preliminary prospectus with the securities regulatory authorities
of all provinces and territories in Canada. The new preliminary prospectus
includes audited financial statements as at January 31, 2016.
The non-financing prospectus is being filed in connection with
the proposed distribution by Manitex of a maximum of 1,256,127
Class "A" common shares of Ortho
RTi to holders of Manitex common shares as a
dividend-in-kind. The dividend would be paid on the basis of one
Class "A" common share of Ortho RTi
for every ten Manitex common shares which are outstanding on the
record date to be fixed by the board of directors of Manitex.
Prior to the filing of the final prospectus, Ortho RTi will apply to list its Class "A"
common shares on a Canadian stock exchange. Listing will be subject
to Ortho RTi fulfilling all of the
listing requirements of that stock exchange.
The preliminary prospectus can be found on SEDAR at
www.sedar.com.
Caution regarding forward-looking statements
This news release may contain certain forward-looking statements
regarding the Company's expectations for future events. Such
expectations are based on certain assumptions that are founded on
currently available information. If these assumptions prove
incorrect, actual results may differ materially from those
contemplated by the forward-looking statements contained in this
press release. Factors that could cause actual results to differ
include, amongst others, uncertainty as to the final result and
other risks. The Company disclaims any intention or obligation to
publicly update or revise any forward- looking statements, whether
as a result of new information, future events or otherwise, other
than as required by security laws.
About Ortho Regenerative Technologies Inc.
Ortho RTi is a Canadian
orthopaedic biotechnology company dedicated to the development of
medical devices that treat unmet needs in the orthopaedic market.
Based on a proprietary biopolymer platform, the company is
developing new regenerative treatments for soft tissue tears in the
shoulder and knee as well as articular cartilage injuries, all
currently with few productive options for repair.
About Manitex Capital Inc.
Manitex Capital Inc. specializes in the acquisition of equity
interests in emerging life science companies and actively
participates in their management. Manitex currently has 12,561,276
common shares outstanding which are quoted for trading on the TSX
Venture Exchange.
TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accept responsibility for the adequacy or accuracy of this
release.
SOURCE Manitex Capital Inc.